Skip to main content

Table 1 Characteristics of the patients at baseline

From: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

  Liraglutide added (n=42) Insulin increasing (n=42) P
Age (years) 51.2 ± 10.5 52.7 ± 10.8 NS
Sex (M/F)     26/16     24/18 NS
Duration of diabetes (years)   9.1 ± 3.6   8.9± 3.6 NS
Body weight (kg) 88.6 ± 11.8 86.3 ± 10.3 NS
BMI (kg/m2)   30.4 ± 3.2   30.3 ± 3.0 NS
Waist Circumference (cm) 105.6 ± 12.6 104.6 ± 10.5 NS
Systolic blood pressure (mmHg)
FBG (mmol/L)  8.36 ± 0.93  8.41 ± 0.86 NS
P2BG (mmol/L) 13.76 ± 1.92 13.80 ± 1.96 NS
HbA1c (%)  8.79 ± 0.86  8.69 ± 0.91 NS
Oral antidiabetic agents
Sulfonylurea  7 (16.7%)  9 (21.4%) NS
Thiazolidinedione 17 (40.5%) 14 (33.3%) NS
α-glucosidase inhibitors   15 (35.7) 13 (31.0%) NS
Glinides 16 (38.1%) 13 (31.0%) NS
Metformin 25 (59.5%) 27 (64.3%) NS
Insulin regimen    
Total daily insulin dose (units/day) 41.2 ± 17.4 41.6 ± 16.5 NS
Insulin glargine only 11 (26.2%) 13 (31.0%) NS
Insulin NPH only 18 (42.9%) 14 (33.3%) NS
Premixed insulin 13 (31.0%) 15 (35.7%) NS
  1. Data are expressed as mean ± S.D. or frequency [n (%)], BMI: body mass index; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; HbA1c: glycosylated haemoglobin A1c; NS: not significant.